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Abstract
Placebo analgesia (PA) depends crucially on the prefrontal cortex (PFC), which is assumed to be responsible for initiating the
analgesic response. Surprisingly little research has focused on the psychological mechanisms mediated by the PFC and
underlying PA. One increasingly accepted theory is that cognitive reappraisal—the reinterpretation of the meaning of
adverse events—plays an important role, but no study has yet addressed the possible functional relationship with PA. We
studied the influence of individual differences in reappraisal ability on PA and its prefrontal mediation. Participants com-
pleted a cognitive reappraisal ability task, which compared negative affect evoked by pictures in a reappraise versus a
control condition. In a subsequent fMRI session, PA was induced using thermal noxious stimuli and an inert skin cream. We
found a region in the left dorsolateral PFC, which showed a positive correlation between placebo-induced activation and
(i) the reduction in participants’ pain intensity ratings; and (ii) cognitive reappraisal ability scores. Moreover, this region
showed increased placebo-induced functional connectivity with the periaqueductal grey, indicating its involvement in des-
cending nociceptive control. These initial findings thus suggest that cognitive reappraisal mechanisms mediated by the
dorsolateral PFC may play a role in initiating pain inhibition in PA.
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Introduction
Our understanding of the neural basis of the placebo effect, in
particular of placebo analgesia (PA), has increased substantially
during the last decade. Several meta-analyses show consistent
increases in activation associated with PA in prefrontal cortex
(PFC) regions, the anterior cingulate cortex (ACC), and the peria-
queductal grey (PAG) (Bingel et al., 2006; Diekhof et al., 2011;
Wager et al., 2011; Wager and Fields, 2013; Atlas and Wager,
2014). Activity in several of these regions correlated with de-
creases in reported pain (Wager and Fields, 2013). Prefrontal
regions are assumed to be responsible for initiating the anal-
gesic response (Wiech et al., 2008; Amanzio et al., 2013; Colloca
et al., 2013), whereas the involvement of the PAG points to possible
activation of descending nociceptive control (Bingel et al., 2006;
Amanzio et al., 2013; Wager and Fields, 2013). Further evidence for
the role of the PFC comes from the reduction in PA when PFC
function is disrupted by repetitive transcranial magnetic stimula-
tion (Krummenacher et al., 2010) or by Alzheimer’s Disease
(Benedetti et al., 2006). Moreover, the structural integrity of white
matter pathways from dorsolateral PFC (DLPFC) to the PAG is
related to the individual placebo analgesic effect (Stein et al., 2012).
Despite the importance of the PFC, surprisingly little re-
search has focused on the psychological mechanisms mediated
by this region and underlying PA. One difficulty is that there is
Received: 22 March 2016; Revised: 9 February 2017; Accepted: 6 March 2017
VC The Author (2017). Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1
Social Cognitive and Affective Neuroscience, 2017, 1–10
doi: 10.1093/scan/nsx033
Original Manuscript
considerable variability in activation of PFC sub-regions across
studies and individuals, and these regions are involved in a range
of other cognitive and affective processes (Kong et al., 2006; Price
et al., 2008; Wiech et al., 2008; Meissner et al., 2011; Atlas and Wager,
2014). One hypothesis about the mechanism behind PA gaining
increasing acceptance is that of emotion regulation, and in particu-
lar, cognitive reappraisal. Cognitive reappraisal is the reinterpret-
ation of the meaning or affective content of adverse events (Gross,
2002). A placebo treatment may trigger cognitive reappraisal mech-
anisms, which then alter the physiological response and subject-
ively experienced negative affect associated with pain (Benedetti
et al., 2005; Wiech et al., 2008; Tracey, 2010). Cognitive reappraisal
has indeed been shown to be successful at moderating self-report
and behavioural measures of pain (Hampton et al., 2015).
Cognitive reappraisal and PA show a remarkable overlap in
neural substrates, with increased activation in the PFC and ACC,
and decreased activation in regions involved in affective pro-
cessing (Benedetti et al., 2005; Diekhof et al., 2011; Amanzio et al.,
2013). Moreover, activity in regions associated with emotional
appraisal (including DLPFC, ventrolateral PFC and orbitofrontal
cortex), rather than cognitive control or pain processing, was
the most predictive of individual differences in the placebo re-
sponse (Wager et al., 2011). In support of this, Lapate et al. (2012)
have demonstrated that a common regulation ability impacts
the experience of both emotion and pain, and placebo has been
shown to modulate emotional perception of pictures and pain
perception similarly (Petrovic et al., 2005; Zhang and Luo, 2009).
Despite the strong indication for a role of cognitive re-
appraisal in producing PA, no study has yet investigated this
possible functional relationship directly. Our aim was to investi-
gate the influence of individual differences in reappraisal ability
on PA and its prefrontal mediation. We expected to find
placebo-related activation in prefrontal regions (especially the
DLPFC) to 1) correlate with independent behavioural measures
of cognitive reappraisal; and 2) to show increased functional
connectivity with regions involved in descending pain modula-
tion. This would provide a first indication for a possible role of
cognitive reappraisal as one underlying mechanism of PA.
Methods
Participants
Thirty healthy volunteers (13 male, mean age: 25.765.5 years)
were recruited through advertisement at the University of
Luxembourg. They gave informed consent according to the
Declaration of Helsinki before participation and were paid remu-
neration for their effort and time. The study was approved by the
Luxembourg national ethics committee (CNER), as well as by
Luxembourg University’s local ethics committee. Twenty-five par-
ticipants were right-handed, two were ambidextrous and three
were left-handed, as assessed with the Edinburgh Handedness
Inventory (EHI; Oldfield, 1971). All participants were in good health,
had normal vision and were free of acute and chronic pain. They
believed that they were taking part in a study about the effect of a
known analgesic cream on brain responses to painful stimulation.
Experimental procedure
Participants were invited to two experimental sessions: first a
laboratory session at the University of Luxembourg, and 1–2
weeks later an fMRI session at the ZithaKlinik hospital in
Luxembourg. During the lab session we assessed cognitive re-
appraisal ability (CRA) of participants using a computer-based
task, as well as self-report of CR using the Emotion Regulation
Questionnaire (ERQ). In the fMRI session, we induced PA during
functional brain imaging. For details please refer to the
Supplementary Material.
CRA task
We used a well-established laboratory task to assess CRA
(Ochsner et al., 2004; Ray et al., 2010; McRae et al., 2012). This task
compares negative affect evoked by pictures in a reappraise ver-
sus a control condition. The task started with detailed in-
structions for the reappraisal condition and a practice session.
Participants were then presented with 30 negative and 15 neu-
tral pictures (for 7 s each) selected from the IAPS picture dataset
(Lang et al., 2008). The task consisted of three conditions (with
15 trials per condition): watching neutral pictures, watching
negative pictures and reappraising negative pictures. Conditions
were presented in pseudo-random order. Each trial started with
a cue word appearing on the computer screen (for 2 s), indicating
the specific instruction for the upcoming trial. This was either the
word ‘look’ (control and neutral condition) or the word ‘decrease’
(reappraisal condition). After each picture, participants rated their
negative feelings on a visual analogue scale (VAS). These ratings
were averaged for each condition, and a CRA score was calculated
as the percent decrease in ratings in the reappraise compared to
the watch negative condition. (For more details about the proced-
ure and instructions, see Supplementary Material).
Questionnaires
We administered the Emotion Regulation Questionnaire (ERQ;
Gross and John, 2003) to assess self-report of habitual use of two
emotion regulation strategies: cognitive reappraisal and expres-
sive suppression (see Supplementary Material). Only the re-
appraisal sub-scores were used in the analyses. In addition, we
measured anxiety and negative affect of participants both at the
start of the lab session and at the start of the scanning session.
To measure anxiety, participants filled out the state subscale of
the State-Trait Anxiety Inventory (STAI; Spielberger, 1989). The
trait subscale was also filled out once at the start of the lab ses-
sion. To measure affect, participants filled out the Positive and
Negative Affect Schedule (PANAS; Watson et al., 1988).
PA procedure
PA was induced using a well-validated protocol (Wager et al.,
2004; Eippert et al., 2009). Pain stimuli of 20 s each were adminis-
tered to the lower forearms and every stimulus was rated ac-
cording to its intensity and unpleasantness on a 100-point
computerised VAS. First, participants underwent a calibration
procedure to determine VAS pain intensity ratings of 40, 60 and
80%. Different skin patches were either treated with a ‘real’ an-
algesic cream or with a ‘control’ cream (in reality identical). In a
manipulation phase, pain stimuli on the ‘real’ cream patch
were surreptitiously lowered to 40%, while participants were
told that all stimuli (6 on each patch) were at 80% of their toler-
ance level. This strengthened the suggestion and expectation of
pain relief. The manipulation phase took place inside the MRI
scanner, but without acquiring images. After this phase, struc-
tural brain images were acquired, followed by the test phase,
during which functional brain images were made. In the test
phase, participants received 15 stimuli in both the placebo and
control condition (i.e. on both a ‘real’ and a ‘control’ cream
patch), all at 60%. A behavioural placebo response score was ob-
tained by calculating the percent reduction in intensity and
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unpleasantness ratings in the placebo condition of the test
phase as compared to the control condition. (For more details
on the placebo protocol and pain stimulation procedure, see
Supplementary Material).
fMRI analyses
Whole-brain functional images were collected during two runs;
the placebo and the control condition. Since we were mainly
interested in individual differences in placebo responses, we
included all participants in the analyses (Enck et al., 2008).
Functional images were pre-processed and analysed using
SPM8 (Wellcome Department of Imaging Neuroscience,
London). (For details on the acquisition and pre-processing of
fMRI images, see Supplementary Material).
For the analyses, the 20-s pain stimuli were divided into an
early (first 10 s) and a late (last 10 s) period based on previous re-
sults regarding neural placebo effects (Wager et al., 2004; Eippert
et al., 2009). First, we verified whether our pain stimuli elicited
reliable pain-related activation in the brain, by collapsing the
control and placebo conditions, and looking at the early and
late pain periods together. We then looked for increases and
decreases in activation in the placebo compared to control
condition—i.e. the neural placebo effect—on a whole-brain
level, during anticipation, early pain and late pain periods.
Additionally, we explored which of these (de-)activated regions
correlated with the reappraisal measures, by adding the CRA
and ERQ scores as covariates.
Because of the putative role of the PFC in initiating PA
(Wiech et al., 2008; Amanzio et al., 2013; Colloca et al., 2013), we
continued to refine our search to a ROI of the PFC, to investigate
clusters where placebo-related increases correlated with
reduced experienced pain and cognitive reappraisal measures.
Finally, to examine functional connectivity between the PFC
and other brain regions, we used a generalised form of context-
dependent psychophysiological interaction analysis (gPPI;
McLaren et al., 2012). This analysis identifies regions that show
changes in functional connectivity as a function of task condi-
tion (placebo versus control). As seed region we used a cluster
in the left DLPFC, as identified in the preceding analyses (this
cluster showed a correlation between placebo-related activation
during anticipation and CRA scores). (For more details on all
fMRI analyses, please refer to the Supplementary Material).
Results
Behavioural placebo response
A summary of all behavioural data is presented in Table 1,
including the mean pain intensity and unpleasantness VAS rat-
ings from the test phase of the placebo protocol. Overall subject-
ive pain report was significantly reduced in the placebo
condition, as compared to the control condition, for intensity
ratings (F(1,29) ¼ 28.19, P < 0.001, Cohen’s d ¼ 0.465) as well
as unpleasantness ratings (F(1,29) ¼ 28.00, P < 0.001, Cohen’s
d ¼ 0.434). The overall placebo-induced reduction was 12.8% for
pain intensity and 16.4% for pain unpleasantness.
Cognitive reappraisal measures
Overall, participants were able to decrease their negative feel-
ings in the reappraise (‘decrease’) condition of the CRA as com-
pared to the control (‘look’) condition (F(1,29) ¼ 33.11, P < 0.001,
Cohen’s d ¼ 0.495). Negativity VAS ratings were reduced by
22.3%. ERQ reappraisal subscale scores ranged from 20
(indicating relatively low self-reported habitual use of re-
appraisal) to 37 (indicating very frequent habitual use of
reappraisal) (Table 1).
Anxiety and negative affect
Mean scores on the STAI and PANAS can be found in Table 1.
STAI scores were below cut-off for clinical anxiety and none of
the scores differed significantly between sessions (STAI state:
F(1,29) ¼ 0.12, P ¼ 0.730, Cohen’s d ¼ 0.066; Positive Affect (PA):
F(1,29) ¼ 0.27, P ¼ 0.607, Cohen’s d ¼ 0.076; Negative Affect (NA):
F(1,29) ¼ 0.11, P ¼ 0.740, Cohen’s d ¼ 0.063).
Correlations between behavioural data and
questionnaires
Two-tailed Pearson correlation coefficients were calculated to
search for correlations. There were no significant correlations be-
tween the CRA and the reappraisal subscale of the ERQ (r ¼ 0.166,
P ¼ 0.382, bias-corrected and accelerated 95% confidence interval
(BCa 95% CI) ¼ [0.188, 0.461]), or between the behavioural pla-
cebo response (reduction in pain intensity ratings) and the two
reappraisal measures (CRA: r ¼ 0.142, P ¼ 0.453, BCa 95% CI ¼
[0.575, 0.345]; ERQ: r ¼ 0.200, P ¼ 0.289, BCa 95% CI ¼ [0.490,
0.191]). We also did not find significant correlations between the
reappraisal measures or the behavioural placebo response and
the anxiety or negative affect scores (all P > 0.05, all lower BCa
95% CI< 0, all upper BCa 95% CI> 0).
Neural pain response
First, we verified whether our pain stimuli elicited reliable pain-
related activation in the brain, by collapsing the control and pla-
cebo conditions, and looking at the early and late pain periods
together. This yielded a network of activations consistent
with pain perception, including the bilateral insula, anterior
cingulate cortex and right (contralateral) secondary somatosen-
sory cortex (see Figure 1. Activations are also reported in
Supplementary Table S1).
Table 1. Summary of all behavioural data
Behavioural measure M (SD)
Placebo
paradigm
VAS Intensity ratings Control 58.8 (15.8)
Placebo 51.5 (15.9)
Difference 12.8%
VAS Unpleasantness ratings Control 55.2 (20.1)
Placebo 46.6 (19.4)
Difference 16.4%
CRA task VAS negativity ratings Control 59.7 (22.8)
Reappraisal 48.4 (25.0)
Difference 22.3%
Questionnaires Start of laboratory session ERQ 29.7 (4.3)
STAI trait 43.3 (9.2)
STAI state 35.4 (8.0)
PA 31.4 (5.3)
NA 14.5 (4.8)
Start of scanning session STAI state 35.9 (6.0)
PA 31.0 (5.5)
NA 14.2 (3.4)
Note: CRA, cognitive reappraisal ability; ERQ, emotion regulation questionnaire;
M, mean; PA, positive affect subscale of the Positive and Negative Affect
Schedule; NA, negative affect subscale of the PANAS; SD, standard deviation;
STAI, state-trait anxiety inventory; VAS, visual analogue scale.
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Whole-brain neural placebo effects
To investigate whether our participants showed a neural placebo
response, we first compared activation in the placebo and control
conditions on a whole-brain level. Placebo-induced reductions in
activation during early pain were found in regions including the
right supplementary motor area (SMA) and precentral gyrus, and
during late pain in the right insula, right amygdala, anterior mid-
cingulate cortex (MCC) and right inferior parietal lobule (Table 2).
Placebo-induced increases in activation were found in regions
including the bilateral thalamus, MCC, left middle frontal gyrus,
left SMA and left precentral gyrus (during anticipation) as well
as in the left brainstem (during early pain, Table 3).
Correlations between whole-brain neural placebo effects
and cognitive reappraisal
Regions which showed a positive correlation between the
placebo-related reductions in activation and cognitive re-
appraisal measures, included the right SMA and right superior/
middle frontal gyri (during early pain), as well as the left insula,
left amygdala, bilateral thalamus, anterior MCC, left caudate
and left putamen (during late pain, Table 4 and Figure S1 in the
Supplementary Material).
Positive correlations between placebo-related increases and
cognitive reappraisal measures were found in regions including
the left insula, brainstem, bilateral middle frontal gyrus and
ACC (during anticipation), as well as in the left superior frontal
gyrus, MCC and right thalamus (during early pain, Table 5 and
Figure S1 in the Supplementary Material).
To summarise, our participant group showed a consistent
neural placebo effect, and moreover, this effect was related to
individual differences in CRA.
Prefrontal mediation of the relationship between PA and
cognitive reappraisal
The main aim of the study was to investigate whether there
were any correlations between placebo-related increases and
independent cognitive reappraisal measures, specifically in the
Fig. 1. Pain-related activation in our task. Control and placebo condition collapsed and early and late pain phase collapsed. Activations are reported in Supplementary
Table S1 (L, left; R, right).
Table 2. Regions showing a reduction in activation during pain in
the placebo condition as compared to the control condition
Region BA MNI coordinates k T Z
x y z
Early pain
SMA/precentral gyrus R 6 14 24 62 28 3.97 3.52
Late pain
STG/Insula/IPL R 13 44 44 20 48 4.21 3.69
STG/insula/amygdala R 38 36 2 14 31 4.06 3.58
MCC/SMA R 31 14 28 46 27 4.03 3.56
ITG R 37 46 40 16 9 3.90 3.47
PHG/lingual gyrus L 19 22 46 8 23 3.83 3.41
Note: BA, Brodman Area; MCC, midcingulate cortex; MNI, Montreal Neurological
Institute; k, cluster size (voxels); L, left; IPL, inferior parietal lobule; ITG, inferior
temporal gyrus; PHG, parahippocampal gyrus; R, right; SMA, supplementary
motor area; STG, superior temporal gyrus.
Table 3. Regions showing increased activation in the placebo condi-
tion as compared to the control condition
Region BA MNI coordinates k T Z
x y z
Anticipation
Cerebellum L 2 66 48 205 4.90 4.15
Thalamus/brainstem L 12 14 2 31 4.53 3.91
MFG/SMA L 6 10 12 60 53 4.26 3.72
Cerebellum L 22 64 42 20 4.05 3.58
Thalamus/VLN R 14 16 14 13 4.04 3.57
Precentral gyrus L 20 24 66 6 3.69 3.31
MCC L 31 6 28 46 6 3.59 3.24
Early pain
PHG/hippocampus R 22 20 18 22 3.94 3.50
PHG/brainstem L 18 26 22 23 3.84 3.42
FFG/PHG L 32 2 30 8 3.76 3.36
Cerebellum R 20 54 44 14 3.72 3.34
Late pain
—
Note: BA, Brodman area; FFG, fusiform gyrus; MCC, midcingulate cortex;
MFG, middle frontal gyrus; MNI, Montreal Neurological Institute;
PHG, parahippocampal gyrus; k, cluster size (voxels); L, left; R, right;
SMA, supplementary motor area; VLN, ventral lateral nucleus.
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PFC, given the putative role of the PFC in initiating the placebo
response. We thus narrowed down our search to a region-of-
interest of the PFC. First, we investigated which PFC regions
showed placebo-induced increases in activation, correlating
with the behavioural placebo response (i.e. reduction in pain in-
tensity ratings). We found significant positive correlations in
several bilateral DLPFC regions for the pain anticipation phase
(Table 6; Figure 2A); participants with stronger activity in these
regions during anticipation of pain in the placebo versus control
condition, rated the stimuli as less intense. There were no
significant negative correlations. For the early pain phase, acti-
vation of the bilateral DLPFC also correlated positively with the
behavioural placebo response (Table 6; Figure 2B). Again, there
were no significant negative correlations. For the late pain
phase, we found no positive or negative correlations between
PFC activation and the behavioural placebo response.
Next, we extracted parameter estimates from these DLPFC re-
gions where activation correlated positively with the behavioural
placebo response, based on ROIs defined as spheres with 5mm
radius centred on the clusters’ peak coordinates. We did this for
Table 4. Regions showing a positive correlation between cognitive reappraisal measures and placebo-related reductions in activation during
pain
Region BA MNI coordinates k T Z CR measure
x y z
Early pain
SFG/MFG/SMA R 6 22 16 66 36 4.46 3.84 CRA
SFG R 8 22 28 58 8 3.70 3.31 CRA
MTG L 50 20 14 8 3.69 3.30 CRA
Caudate R 18 20 22 8 3.67 3.29 CRA
— ERQ
Late pain
Putamen/globus pallidus L 18 2 2 38 4.08 3.59 CRA
Caudate L 20 6 24 12 3.85 3.42 CRA
Thalamus R 12 20 8 7 3.74 3.34 CRA
Thalamus L 8 24 2 10 3.71 3.32 CRA
Insula L 28 18 24 9 3.65 3.27 ERQ
MCC L 12 4 32 14 4.17 3.65 ERQ
PHG/amygdala L 28 2 32 21 4.12 3.61 ERQ
Note: BA, Brodman area; CR, cognitive reappraisal; CRA, cognitive reappraisal ability test score; ERQ, emotion regulation questionnaire; L, left; MCC, midcingulate cor-
tex; MNI, Montreal Neurological Institute; MFG, middle frontal gyrus; MTG, middle temporal gyrus; k, cluster size (voxels); PHG, parahippocampal gyrus; R, right;
SMA, supplementary motor area; SFG, superior frontal gyrus. These activations are also shown in Figure S1 in the Supplementary Material.
Table 5. Regions showing a positive correlation between cognitive reappraisal measures and placebo-related increases
Region BA MNI coordinates k T Z CR measure
x y z
Anticipation
IPL/supramarginal gyrus/Insula L 42 50 22 196 5.23 4.33 CRA
Middle temporal pole L 38/21 50 14 32 18 4.48 3.85 CRA
Brainstem R 12 24 10 15 4.25 3.70 CRA
Middle frontal gyrus L 10 36 40 20 26 4.21 3.68 CRA
Middle frontal gyrus R 9 36 20 32 18 3.96 3.50 CRA
Insula/IPL L 13 40 30 20 10 3.89 3.45 CRA
Insula/IFO L 13/44 38 14 16 19 3.88 3.44 CRA
ACC L 32 14 36 18 5 3.73 3.33 CRA
Medial frontal gyrus L 9/32 20 36 22 5 3.52 3.18 CRA
— ERQ
Early pain
— CRA
Putamen/pallidum R 30 10 4 34 4.50 3.87 ERQ
SFG/paracentral lobule L 6 10 18 74 25 4.08 3.59 ERQ
Thalamus R 6 22 4 5 3.90 3.46 ERQ
Medial SFG L 10 8 58 2 8 3.81 3.39 ERQ
Precuneus/MCC R 31 12 46 38 9 3.71 3.32 ERQ
Late pain
— CRA
Superior temporal gyrus R 40 48 8 14 4.37 3.78 ERQ
Note: ACC, anterior cingulate cortex; BA, Brodman Area; CR, cognitive reappraisal; CRA, cognitive reappraisal ability test score; ERQ, emotion regulation questionnaire;
k, cluster size (voxels); L, left; IPL, inferior parietal lobule; IFO, inferior frontal operculum; MCC, midcingulate cortex; MNI, Montreal Neurological Institute; SFG, superior
frontal gyrus; R, right. These activations are also shown in Figure S1 in the Supplementary Material.
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three contrasts of interest, namely placebo versus control during
anticipation, early pain and late pain. We correlated these par-
ameter estimates with our behavioural scores on the CRA labora-
tory task and with responses on the reappraisal subscale of the
ERQ. We found significant positive correlations between the CRA
scores and parameter estimates from the anticipation phase for
two of these six clusters, one in the left and one in the right
DLPFC (see Figure 2C). Participants with stronger activity in these
regions during placebo-related anticipation of pain reduction
also reported less negative affect when applying cognitive re-
appraisal during the lab task. The remaining clusters did not cor-
relate with either cognitive reappraisal measure.
In a subsequent analysis, we added the CRA scores and ERQ
reappraisal sub-scores as covariates to the placebo versus con-
trol contrasts, to examine the PFC directly for correlations be-
tween reappraisal measures and placebo-related activation
during the different pain phases. For the anticipation phase, we
found significant positive correlations with the CRA score in 3
clusters in bilateral DLPFC (Table 7; Figure 3A), and no negative
correlations. There were no significant correlations with the
ERQ. For the early pain phase, we found no correlations with
the CRA, but a significant positive correlation in the left medial/
orbitofrontal cortex with the ERQ reappraisal sub-score (Table 7;
Figure 3B) (and no negative correlations). For the late pain
phase, we found no positive or negative correlations between
prefrontal activation and either cognitive reappraisal measure.
Between these two approaches to the analysis, there was a
close convergence in the left DLPFC area, where the cluster identi-
fied using the first method (34, 18, 30) overlapped with a cluster
identified using the second method (38, 14, 16). Both analyses
found a positive correlation between placebo-related activation
during anticipation and the CRA test score in this DLPFC region.
We then performed a mediation analysis, with the behav-
ioural placebo response as dependent variable, the CRA score as
independent variable, and the DLPFC activation (parameter esti-
mates from the left DLPFC cluster emerging from both analyses
above) as potential mediator. This revealed a small but signifi-
cant mediation effect (ab¼ 0.14, 95% BCa CI [0.001, 0.403]). CRA
thus partially predicted the subjective pain reduction in the pla-
cebo paradigm through the activation of the DLPFC.
Psychophysiological interaction
Finally, we investigated the task-related functional connectivity
of the PFC with other brain regions, using a psychophysiological
interaction (PPI) analysis (see methods and Supplementary
Material). As seed region (see Figure 4A) we defined the left
DLPFC cluster identified in the two correlation analyses above,
showing a significant positive correlation between placebo-
related activation during anticipation and the CRA score (38,
14, 16). We entered the PPI contrast images for placebo versus
control during anticipation from each participant into a group
analysis, and found three regions that showed increased con-
nectivity with the DLPFC as a function of task condition, namely
the PAG, putamen and left middle frontal gyrus (Table 8, Figure
4A and B, and Supplementary Figure S2). These regions showed
Fig. 2. Prefrontal cortex regions showing a positive correlation between placebo-induced activation and behavioural placebo analgesia. (A) Clusters showing a correl-
ation during the anticipation phase. (PA ¼ placebo analgesia, L and R indicate left and right for the transversal slice). (B) Clusters showing a correlation during the early
pain phase. For illustrative purposes, activations in A and B are shown at p(unc) < 0.005 and images are masked to only show PFC activations. Shown clusters are
reported (at p(unc) < 0.001) in Table 6. (C) Significant correlations between CRA scores and parameter estimates extracted from DLPFC clusters. (DLPFC ¼ dorsolateral
prefrontal cortex, CRA ¼ cognitive reappraisal ability task scores).
Table 6. Prefrontal cortex regions showing a positive correlation be-
tween placebo-induced activation and behavioural PA
Region BA MNI coordinates k T Z
x y z
Anticipation
DLPFC L 9 38 42 34 11 3.90 3.45
DLPFC L 9 46 34 32 3.65 3.27
DLPFC R 8 32 38 46 4 3.77 3.36
DLPFC R 8 50 18 46 8 3.75 3.35
Early pain
DLPFC L 9 34 18 30 24 4.50 3.87
DLPFC R 6 40 4 52 10 4.06 3.57
Note: These clusters are also shown in Figure 2A and B. BA, Brodman area;
DLPFC, dorsolateral prefrontal cortex; MNI, Montreal Neurological Institute; k,
cluster size (voxels); L, left; R, right).
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increased functional connectivity with the DLPFC during the
placebo condition, as compared to the control condition.
Discussion
Although the notion that cognitive reappraisal may play a role
in PA has gained increasing acceptance, this is the first study to
investigate this functional relationship directly. We demon-
strated placebo-induced decreases in activation during pain in
typical pain-processing structures, including the insula, amyg-
dala, anterior MCC and sensorimotor cortex. These regions have
consistently been found to be reduced following a placebo pro-
cedure (Wager et al., 2011; Wager and Fields, 2013; Atlas and
Wager, 2014). Importantly, this neural PA effect was related to
individual differences in reappraisal measures: individuals with
greater reappraisal success in the lab task (CRA) or more fre-
quent self-reported use of cognitive reappraisal (ERQ) also
showed smaller neural responses to noxious heat under pla-
cebo. This suggests that there is indeed a link between PA and
cognitive reappraisal. When we then refined our search to the
PFC, we identified a left DLPFC cluster, where placebo-induced
increase in activation was modulated by individual differences
in performance in the reappraisal lab task. The identification of
this cluster was corroborated by two different analyses, both
finding a significant positive correlation between placebo-
related activation during anticipation of pain reduction and the
CRA test scores. Participants with stronger activity in this
cluster reported less negative affect when applying cognitive re-
appraisal in the lab task. Importantly, activity in this left DLPFC
region also correlated positively with the behavioural placebo
response, indicating its direct involvement in the down-
regulation of pain. Furthermore, the region showed increased
placebo-related functional connectivity to the PAG, an import-
ant structure of the descending pain control system (Basbaum
and Fields, 1984). Finally, a mediation analysis showed that CRA
partially predicted the subjective pain reduction, through the
activation of the DLPFC. Our findings thus suggest that there
may be a role for the left DLPFC in mediating PA and initiating
pain inhibition through cognitive reappraisal mechanisms.
Interestingly, cognitive reappraisal has been termed an ‘ante-
cedent-focused’ regulatory strategy, which can be employed be-
fore the onset of an aversive event (Gross, 2002). We have
confirmed previous demonstrations (e.g. Wager et al., 2004) of
prefrontal activation during anticipation of pain reduction. This
reinforces the idea that it is the expectations one has before a
painful event that trigger a cognitive frame in which the pain is
reappraised.
Dorsolateral PFC in PA and cognitive reappraisal
The left DLPFC has been implicated consistently both in PA and
in cognitive reappraisal studies, often within 10 mm from our
cluster peak (see, for example, these meta-analyses on PA:
Wager et al., 2011; Atlas and Wager, 2014; and on cognitive re-
appraisal: Buhle et al., 2014). Anticipatory activation in the same
Table 7. Prefrontal cortex regions showing a positive correlation between placebo-induced activation and cognitive reappraisal measures
Region BA MNI coordinates k T Z CR measure
x y z
Anticipation
DLPFC L 10 36 40 20 26 4.21 3.68 CRA
DLPFC R 9 36 20 32 14 3.96 3.50 CRA
DLPFC L 46 38 14 16 19 3.88 3.44 CRA
Early pain
Medial/Orbito-frontal gyrus L 10 8 58 2 8 3.81 3.39 ERQ
Notes: Clusters also shown in Figure 3A and B. BA, Brodman Area; CRA, cognitive reappraisal ability test score; CR, cognitive reappraisal; DLPFC, dorsolateral prefrontal
cortex; ERQ, emotion regulation questionnaire; MNI, Montreal Neurological Institute; k, cluster size (voxels); L, left; R, right.
Fig. 3. Prefrontal cortex regions showing a positive correlation between placebo-induced activation and cognitive reappraisal measures. (A) Clusters showing a positive
correlation during the anticipation phase with scores on the cognitive reappraisal ability laboratory task (CRA). (L ¼ left, R ¼ right). (B) Cluster showing a positive correl-
ation during the early pain phase with scores on the emotion regulation questionnaire (ERQ). Images are masked to only show PFC activations, and activations are re-
ported in Table 7.
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left DLPFC region, amongst others, predicted the magnitude of
the placebo response across a large sample of studies (Wager
et al., 2011). The DLPFC has also been specifically associated
with belief-related modulation of pain (Wiech et al., 2008, 2014),
perceived control over pain (Salomons et al., 2004, 2007; Wiech
et al., 2006), supporting affective value, expectancy maintenance
and regulation of emotion (Miller and Cohen, 2001; Kringelbach,
2005; Wager, 2005; Petrovic et al., 2010), modulation of aversive
stimuli (Wiech et al., 2008), and emotional detachment from
pain (Wiech and Tracey, 2009; Tracey, 2010). Notably, these are
all functions consistent with cognitive reappraisal mechanisms.
In support of the role of the DLPFC in PA, Krummenacher et al.
(2010) have shown that repetitive transcranial magnetic
stimulation of bilateral DLPFC completely blocked PA. Within
the reappraisal literature, the DLPFC is considered an area re-
sponsible for reinterpretation (encoding contextual aspects of
stimuli) and for constructing a ‘new story’ about the meaning of
a stimulus (Ochsner and Gross, 2008).
Connectivity of DLPFC
The demonstration of increased connectivity between DLPFC
and PAG in our study is in line with the idea that prefrontal
mechanisms trigger pain control systems descending from the
brainstem (Basbaum and Fields, 1984; Fields, 2004). The obser-
vation of increased functional connectivity between DLPFC and
PAG is not entirely new. Wager et al. (2004) already demon-
strated in a PA paradigm that bilateral DLPFC activation during
anticipation of pain reduction correlated with placebo-
increased anticipatory activation of the PAG. Subsequent stud-
ies have confirmed this coupling (Wager et al., 2007; Eippert
et al., 2009; Wager et al., 2011). Structural connections between
the DLPFC and PAG have also been demonstrated (Mantyh,
1982; Linnman et al., 2012), and have been shown to correlate
with the placebo analgesic response (Stein et al., 2012).
Moreover, greater effective connectivity between the left DLPFC
and PAG was predictive of the placebo response (Sevel et al.,
2015). Our study, however, is the first to link the DLPFC, and its
connectivity with the PAG, to cognitive reappraisal as a possible
underlying mechanism. The placebo-induced connectivity be-
tween DLPFC and putamen is also interesting given the role of
the striatum in dopaminergic pain regulation (Hagelberg et al.,
2002, 2004). The ventral striatum has consistently been found
activated in PA studies (e.g. Atlas and Wager, 2014), and is asso-
ciated with reward processing (Scott et al., 2007) and learning
about affective value (Schoenbaum et al., 2009; Liljeholm and
O’Doherty, 2012). Alternatively, the putamen involvement could
be related to the inhibition of motor responses to the pain stim-
uli during the placebo condition (Bingel et al., 2004). Finally, the
middle frontal gyrus cluster showing increased connectivity
with the DLPFC is a region that has previously been associated
with the cognitive reappraisal of high versus low intensity nega-
tive emotions (Silvers et al., 2014), and may thus well play an im-
portant role in placebo-induced cognitive reappraisal.
Conclusion, limitations and perspectives
Our data point in the direction of a possible role of cognitive re-
appraisal, mediated by the DLPFC, as an underlying mechanism
of PA. Placebo-induced activation of the left DLPFC (i) correlated
positively with the reduction in subjectively experienced pain
by participants; (ii) correlated positively with an independent
behavioural measure of cognitive reappraisal and (iii) was func-
tionally connected to the PAG, a key area of the descending pain
control system. Our participant group also showed a clear neu-
ral PA effect (placebo-related reductions in pain-processing re-
gions) which was related to individual differences in cognitive
reappraisal. This suggests that the PAG network was indeed
related to pain reduction in our group.
This relationship between PA and cognitive reappraisal is
still rather indirect. An even stronger argument for a direct func-
tional relationship would be to show an overlap in neural acti-
vation during PA and cognitive reappraisal within individuals,
Fig. 4. Functional connectivity of the left dorsolateral prefrontal cortex. (A) The
seed region (DLPFC) is indicated by the blue dot, whereas the areas showing
increased placebo-related connectivity with the seed region are indicated by the
green, red and yellow dots. These clusters are reported in Table 8 and also
shown in Figure S2 in the Supplementary Material. (B) Connectivity of the PAG,
putamen and MFG with the left DLPFC during anticipation in the control
and placebo condition; mean eigenvariates from the PPI contrasts extracted
for illustrative purposes from 5mm radius spheres around peak coordinates.
(PAG ¼ periaqueductal grey, MFG ¼ middle frontal gyrus, DLPFC ¼ dorsolateral
prefrontal cortex, *P < 0.05, **P < 0.001).
Table 8. Regions showing increased task-dependent connectivity
with the left dorsolateral prefrontal cortex
Region BA MNI coordinates k T Z
x y z
Middle frontal gyrus L 6 30 8 42 34 3.79 3.39
Putamen R 28 14 6 31 3.71 3.33
PAG L 2 30 26 21 3.18 2.92
Notes: Clusters are also shown in Figure 4A and Supplementary Figure S2. BA,
Brodman area; MNI, Montreal Neurological Institute; k, cluster size (voxels);
PAG, periaqueductal grey; L, left; R, right.
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or to show the direct influence of a reappraisal manipulation
within a placebo paradigm. Another demonstration of a direct
link would be a correlation between cognitive reappraisal test
scores and the magnitude of behavioural PA. One possible ex-
planation for why we failed to observe such a correlation could
be that the percentage of reduction in pain intensity scores is
too crude a measure to characterise the complex processes that
underlie a placebo manipulation, and that the neural processes
taking place may result in other behavioural modulations not
captured by the pain intensity ratings. Another possibility is
that our reappraisal lab task was not optimally designed to
measure the type of reappraisal processes that may be involved
in PA. The lab task was based on negative pictures whereas
pain stimuli represent a completely different type of stimulus.
We employed this reappraisal lab task because it is a well-
established and validated task. Moreover, there is some evi-
dence that reappraisal impacts the experience of negative
pictures and pain similarly (Lapate et al., 2012). However, the
exact processes involved in PA and reappraisal of pictures may
differ, and a cognitive reappraisal lab task targeting pain stimuli
may have been more appropriate. These issues need to be ad-
dressed in future studies.
One limitation of this study is the use of mainly uncorrected
statistical thresholds in the neuroimaging analyses. Since this
study was explorative, we have taken a liberal statistical ap-
proach, allowing for Type I error rates to rise in the interest of
keeping the Type II error rate low (Forstmeier et al., 2016).
However, results should be interpreted cautiously and should
be corroborated using better control for false positives, possibly
with a larger sample size and modified experimental and scan-
ning protocols to yield more robust activations.
It would be interesting to further study the link between PA
and cognitive reappraisal, by taking into account current know-
ledge about cognitive reappraisal and emotion regulation gener-
ally, and testing corresponding predictions for PA. For example,
we know that self-regulatory resources are limited and self-
regulation is cognitively demanding. When such self-regulatory
resources are experimentally depleted, and if PA depends in
part on these resources, will the placebo response be decreased
correspondingly? Future studies could explore these possible
venues to further our understanding of the mechanisms behind
the placebo effect. Finally, a potential clinical implication of a
relationship between cognitive reappraisal and PA is that clin-
icians may actively trigger or instil self-regulation techniques to
maximise the benefit of patients from medication (Schneider
and Kuhl, 2012).
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